Continue with FacebookLooking to list your PhD opportunities? Log in here.
ovarian cancer PhD Projects, Programmes & Scholarships
We have 11 ovarian cancer PhD Projects, Programmes & Scholarships
PhD saved successfully
Discovering molecular targets to treat ovarian cancer
Background. Ovarian cancer is the leading cause of death from gynaecological malignancies. Subtypes with mutations in a member of the SWI/SNF (SWItch/Sucrose Non-Fermentable) chromatin remodelling complex are particularly chemoresistant. Read more
Dissecting mechanism of drug responses to novel anti-cancer therapies
Repurposing drug screens with compounds that have already gained FDA approval can accelerate the identification of new therapies to treat an illness and in the cancer setting extend life or provide compassionate care. Read more
Developing novel therapeutic strategies to better treat Triple Negative Breast Cancer
One in two people will develop cancer in their lifetime and it is a leading cause of death. While significant progress has been made in the treatment of some cancers, there still remain some forms of the disease with limited treatment options and poor outcome. Read more
New Anticancer Therapeutics Based on Luminescent Transition Metal Complexes
Cancer is one of the leading causes of death around the world. Over 50% of cancer tumours are treated with platinum-based metal complexes, like cisplatin and its derivatives. Read more
Last chance to apply
Characterising the mode of action of a novel anti-AT1R antibody (ATN-E11) on the proliferation, migration and angiogenesis in a range of cancer cell lines
Fixed term contract for 3 years, commencing January 2024. Bursary of £18,622 per annum and a full fee-waiver for UK tuition fees. Read more
Synthesis of New Anti-Cancer Agents and Pharmacogenomics of BRCA-mutated Cancers in the Qatar Population
The group has published on the discovery of heterocyclic quinone anti-cancer agents with specificity towards hypoxic cells associated with solid tumours… Read more
Personalising cancer treatment with modelling tumour evolution based on genomics biomarkers and PK/PD
Tumour heterogeneity is a major problem limiting the efficacy of targeted oncological therapies. Most advanced tumours eventually become resistant to the treatments, ultimately making the patient succumb to metastatic disease. Read more
The role of microtubule regulators in the progression of cancer: investigating the link between BRCA2 and depolymerising kinesins.
The mitotic kinesin KIF2C/MCAK regulates microtubule length in the mitotic spindle and plays a role in preventing chromosome-microtubule attachment errors. Read more
Investigating the role of USP17 in EMT
USP17 is over-expressed in a range of primary tumours (NSCLC, breast, colorectal, cervical, ovarian, osteosarcoma) and its depletion blocks the growth, and migration, of cells from all of these cancer types. Read more
Regulation of genome stability and human disease
Poly(ADP-ribose) polymerases (PARPs) are the major family of enzymes that synthesize an abundant posttranslational protein modification called ADP-ribosylation. Read more
- 1
